Semaglutide Shows Promise for Non-Diabetic Chronic Kidney Disease in Landmark SMART Trial Exciting news emerged from Kidney Week 2024 as the landmark SMART trial unveiled promising results for semaglutide (Ozempic/Wegovy) …
Tag:
rheumatology
-
-
Semaglutide Shows Promise in Reducing Cardiovascular and All-Cause Mortality in Patients with Type 2 Diabetes and CKD New data from the FLOW trial, presented at the American Society of Nephrology’s …
-
Hiddo Heerspink, PharmD, PhDCredit: George Institute for Global Health Semaglutide Shows Promise in Managing Chronic Kidney Disease Without Diabetes A recent clinical trial suggests semaglutide (Ozempic) may hold significant potential …
-
Health
. Empagliflozin Benefits on Kidney Disease Progression, Death Continue for 1 Year Post-Discontinuation
Will Herrington, MA, MBBS, MD, FRCP, FERA Credit: Oxford University Empagliflozin Continues to Protect Kidney Health After Trial Completion New data from the EMPA-KIDNEY trial presented at ASN Kidney Week …
-
Jennifer Yi-Chun-Lai Yee, MD, PhD, MPHCredit: Michigan Medicine Sparsentan Shows Promise for Patients with Genetic Focal Segmental Glomerulosclerosis (gFSGS) A recent analysis of the DUPLEX trial, the largest clinical trial …
-
Intellia Therapeutics’ Nex-Z Shows Promise for Treating ATTR-CM Intellia Therapeutics is making waves in the fight against ATTR amyloidosis with cardiomyopathy (ATTR-CM) with its groundbreaking gene editing therapy, nex-z (formerly …
Older Posts